


I Encuentro de Jóvenes Investigadores

CIBERONC

14 de Noviembre 2018
*Escuela Nacional de Sanidad,
Madrid*



Programa de Formación y Movilidad de CIBERONC

15 – Nov. Madrid

Jornadas de Formación Conjuntas CIBERES -CIBERONC

ciberes
Centro de Investigación Biomédica en Red
Enfermedades Respiratorias

ciberonc
Centro de Investigación Biomédica en Red
Cáncer



ISC
Instituto de Salud Carlos III

Patrocinado por:



9:30 Registro

10:00 **Bienvenida**

Joaquín Arribas. VHIO. *Director Científico de CIBERONC*

Amparo Cano. UAM. *Coordinadora del Programa de Formación y Movilidad*

10:30 **Programa de Tumores Gastro-Intestinales**

Chair: Maribel González. IDIBELL

Rodrigo Toledo. VHIO. *Líder de biopsia líquida y biomarcadores*

Pilar Mur. *Germline mutations in POLE and POLD1 in several forms of hereditary cancer*

Alberto Bueno. *Enhancer Methylation changes during Induced Transdifferentiation of Leukemia B-Cells to Macrophages*

11:10 **Programa de Cáncer de Mama**

Chair: Irene Rius. VHIO

Alberto Ocaña. CRIB. *Líder de resistencia a fármacos y nuevas terapias*

Enrique Arenas. *Identification of novel mechanisms of resistance against the redirection of T-cell effector function for cancer therapy*

Faiz Bilal. *Role of Slug in the emergence of resistance to MAPK inhibition*

11:50 **Pausa café**

12:10 **Sesión de pósteres**

12:30 **Programa de Tumores del Tracto Respiratorio**

Chair: Patricia Yagüe. CNIO

Silvestre Vicent. CIMA

Karmele Valencia. *The MIR181AB1 cluster is necessary for the initiation and maintenance of mutant KRAS-driven lung adenocarcinoma*

Héctor Amado. *Lung-tumorspheres as an effective in vitro and in vivo platform for screening anti-cancer stem cell drugs*

13:10 **Programa de Tumores Hematológicos**

Chair: Javier I. Muñoz. CIC Salamanca

Patricia Pérez Galán. IDIBAPS. *Líder de modelo experimentales*

Laia Rosich. *Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia*

Cristina Pérez. *Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells in the tumor Immune MicroEnvironment (TIME) of Multiple Myeloma*

13:50 **Almuerzo**

14:30 **Sesión de pósteres– Foto de evento**

15:00 **Oportunidades profesionales después del doctorado**

Manolo Castellano. *Scientific Careers Consultant*

15:45 **Programa de Tumores de Baja Prevalencia**

Chair: Berta Roman. IRB-Lleida

Pedro Berraondo. CIMA. *Líder de inmuno-Oncología*

Lourdes Hontecillas. *Histone Lysine Methyltransferase G9a Inhibition modulates cell metabolism and reduces tumorigenicity in Ewing Sarcoma*

Susana Martín. *3D bioprinted hydrogels as an experimental model for Neuroblastoma*

16:25 **Programa de Mecanismos de Progresión Tumoral**

Chair: Luis Fco. Lorenzo. CIC Salamanca

Víctor Quesada. UOVI. *Líder de bioinformática y ómicas del cáncer*

Alejandra Bernardini. *Patterns of response and resistance to programmed cell death-1 blockade in patients with advanced urothelial tumor*

Rubén Fernández. *Rho GEFs and GAPs as new potential therapeutic targets in LUAD: an in silico modeling*

17:05 **Mesa Redonda 1: Tránsito de resultados científicos**

Chair: Berta Roman. IRB-Lleida

Alexander de la Fuente. Nasasbiotech. *CEO*

Luzma García. CIBER. *Responsable de Tránsito de la Unidad Técnica*

Alejandro Mut. Celgene. *Medical Advisor Oncology.*

17:35 Trivial

18:00 **Mesa Redonda 2: La vida en el laboratorio**

Chair: Javier I. Muñoz. CIC Salamanca

Amparo Cano. UAM. *Coordinadora del Programa de Formación y Movilidad*

Luis Paz-Ares. Hospital Universitario 12 de Octubre. *Coordinador del Programa Tumores de Tracto Respiratorio*

Rodrigo Toledo. VHIO. *Líder de biopsia líquida y biomarcadores*

Patricia Yagüe. CNIO

Luis Fco. Lorenzo. CIC Salamanca

18:30 **Entrega de premios**

19:00 Clausura del encuentro

Pósteres presentados:

01GIT

Differential expression of microRNAs in circulating exosomes depending on RAS mutational status in metastatic colorectal cancer patients

02GIT

SETD6 dominant negative mutation in Familial Colorectal Cancer Type X

03GIT

Germline CNV detection in genetic diagnostics: benchmark of algorithms for CNV calling from NGS data at single exon resolution

04GIT

Germline RNF43 mutations are a rare cause of serrated polyposis

05GIT

Comprehensive constitutional genetic and epigenetic characterization of Lynch-like individual

06GIT

Comprehensive Analysis of Fanconi Anemia Genes in Hereditary Cancer

07BC

Unanticipated therapeutic combinations in cancer: therapy-induced senescence and antibody-drug conjugates (ADCs)

08RTT

PD-1 and Id-1 Combined blockade impacts tumor growth and survival through PD-L1 expression and tumor infiltration by immune-related cell

09RTT

Exosomal miRNA profile in NSCLC: differential cargo between 2D and 3D cultures

10RTT

An expression signature characterizes cancer stem cells from lung adenocarcinoma patients

11RTT

Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven lung adenocarcinoma (LUAD) via regulation of a FOSL1 network

12HT

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia

13HT

Identification of tipifarnib sensitivity noninvasive biomarkers in T-cell lymphoma

14HT

Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination

15HT

Understanding Multiple Myeloma (MM) And Light-Chain Amyloidosis (AL) Biology Through The Dissection of The Normal Plasma Cell (PC) Development

16LPT

Characterization of extracellular matrix elements in neuroblastoma xenografts models

17LPT

ABTL0812 treatment in endometrial cancer

18MTP

Preliminary evaluation of the effects of two butyrate derivatives on human bladder cancer cell lines and monocytes as HDAC inhibitor and immune modulator

19MTP

The characterization of the FOXM1 transcription factor as a suitable biomarker of CDK4 inhibition in bladder cancer

20MTP

Cdk4/6-inhibitor as a novel therapeutic approach for Bladder Cancer independently of RB1 status

Patrocinado por:

